Details for New Drug Application (NDA): 208219
✉ Email this page to a colleague
The generic ingredient in LOTEMAX SM is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
Summary for 208219
Tradename: | LOTEMAX SM |
Applicant: | Bausch And Lomb Inc |
Ingredient: | loteprednol etabonate |
Patents: | 2 |
Pharmacology for NDA: 208219
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for 208219
Suppliers and Packaging for NDA: 208219
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219 | NDA | Bausch & Lomb Incorporated | 24208-507 | 24208-507-01 | 1 BOTTLE in 1 CARTON (24208-507-01) / .5 g in 1 BOTTLE |
LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219 | NDA | Bausch & Lomb Incorporated | 24208-507 | 24208-507-02 | 1 BOTTLE in 1 CARTON (24208-507-02) / 5 g in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;OPHTHALMIC | Strength | 0.38% | ||||
Approval Date: | Feb 22, 2019 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 23, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 26, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY |
Complete Access Available with Subscription